Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Macromolecular carrier systems for targeted drug delivery: pharmacokinetic considerations on biodistribution.

Literature DB >> 8792417

Macromolecular carrier systems for targeted drug delivery: pharmacokinetic considerations on biodistribution.

Abstract

This review article describes the current status and future perspectives of site-specific drug delivery by means of macromolecular carrier systems. Basic aspects and recent advances of targeted delivery of 1) conventional drugs, 2) protein drugs, and 3) gene medicines including antisense oligonucleotides and plasmid DNA, are reviewed from a pharmacokinetic perspective. Successful in vivo application of macromolecular carrier systems requires pharmacokinetic considerations at whole body, organ, cellular and subcellular levels. The integration of simultaneous research progress in the multidisciplinary fields such as biochemistry, cell and molecular biology, pharmacology, and pharmacokinetics will accelerate the emergence of marketed drugs with macromolecular carrier systems.

Entities: Chemical

Mesh：

Substances：

Year: 1996 PMID： 8792417 DOI： 10.1023/a:1016084508097

Source DB: PubMed Journal: Pharm Res ISSN： 0724-8741 Impact factor: 4.200

43 in total

Review 1. Macromolecular drug carrier systems in cancer chemotherapy: macromolecular prodrugs.

Authors: Y Takakura; M Hashida
Journal: Crit Rev Oncol Hematol Date: 1995-03 Impact factor: 6.312

Review 2. Generation of cytotoxic agents by targeted enzymes.

Authors: P D Senter; P M Wallace; H P Svensson; V M Vrudhula; D E Kerr; I Hellström; K E Hellström
Journal: Bioconjug Chem Date: 1993 Jan-Feb Impact factor: 4.774

3. Galactosylated histone-mediated gene transfer and expression.

Authors: J Chen; R J Stickles; K A Daichendt
Journal: Hum Gene Ther Date: 1994-04 Impact factor: 5.695

4. Receptor-mediated gene transfer into human T lymphocytes via binding of DNA/CD3 antibody particles to the CD3 T cell receptor complex.

Authors: M Buschle; M Cotten; H Kirlappos; K Mechtler; G Schaffner; W Zauner; M L Birnstiel; E Wagner
Journal: Hum Gene Ther Date: 1995-06 Impact factor: 5.695

5. Gene transfer in vivo: sustained expression and regulation of genes introduced into the liver by receptor-targeted uptake.

Authors: J C Perales; T Ferkol; H Beegen; O D Ratnoff; R W Hanson
Journal: Proc Natl Acad Sci U S A Date: 1994-04-26 Impact factor: 11.205

6. Improvement of therapeutic effect of human recombinant superoxide dismutase on ischemic acute renal failure in the rat via cationization and conjugation with polyethylene glycol.

Authors: K Mihara; Y Oka; K Sawai; Y Takakura; M Hashida
Journal: J Drug Target Date: 1994 Impact factor: 5.121

7. Enhancement of tumouricidal activity of daunomycin by receptor-mediated delivery. In vivo studies.

Authors: B Mukhopadhyay; A Mukhopadhyay; S K Basu
Journal: Biochem Pharmacol Date: 1993-09-01 Impact factor: 5.858

8. Identification of a monoclonal antibody, TV-1, directed against the basement membrane of tumor vessels, and its use to enhance the delivery of macromolecules to tumors after conjugation with interleukin 2.

Authors: A L Epstein; L A Khawli; J L Hornick; C R Taylor
Journal: Cancer Res Date: 1995-06-15 Impact factor: 12.701

9. Tumor localization and in vivo antitumor activity of the immunoconjugate composed of anti-human colon cancer monoclonal antibody and mitomycin C-dextran conjugate.

Authors: A Noguchi; T Takahashi; T Yamaguchi; K Kitamura; Y Takakura; M Hashida; H Sezaki
Journal: Jpn J Cancer Res Date: 1991-02

10. Inhibition of leukaemia cell proliferation by folic acid-polylysine-mediated introduction of c-myb antisense oligodeoxynucleotides into HL-60 cells.

Authors: G Citro; C Szczylik; P Ginobbi; G Zupi; B Calabretta
Journal: Br J Cancer Date: 1994-03 Impact factor: 7.640

33 in total

1. Enhanced accumulation of sialyl Lewis X-carboxymethylpullulan conjugate in acute inflammatory lesion.

Authors: K Horie; M Sakagami; K Kuramochi; K Hanasaki; H Hamana; T Ito
Journal: Pharm Res Date: 1999-02 Impact factor: 4.200

Review 2. Designing dendrimers for drug delivery and imaging: pharmacokinetic considerations.

Authors: Wassana Wijagkanalan; Shigeru Kawakami; Mitsuru Hashida
Journal: Pharm Res Date: 2010-12-23 Impact factor: 4.200

Review 3. Design and pharmacokinetical aspects for the use of inorganic nanoparticles in radiomedicine.

Authors: Victor Puntes
Journal: Br J Radiol Date: 2015-10-23 Impact factor: 3.039

4. EphA2 targeting peptide tethered bioreducible poly(cystamine bisacrylamide-diamino hexane) for the delivery of therapeutic pCMV-RAE-1γ to pancreatic islets.

Authors: Katherine S Blevins; Ji Hoon Jeong; Mei Ou; Jonathan H Brumbach; Sung Wan Kim
Journal: J Control Release Date: 2011-10-28 Impact factor: 9.776

Review 5. Gene modulation for treating liver fibrosis.

Authors: Kun Cheng; Ram I Mahato
Journal: Crit Rev Ther Drug Carrier Syst Date: 2007 Impact factor: 4.889

6. Synthesis and in vitro characterization of novel dextran-methylprednisolone conjugates with peptide linkers: effects of linker length on hydrolytic and enzymatic release of methylprednisolone and its peptidyl intermediates.

Authors: Suman Penugonda; Anil Kumar; Hitesh K Agarwal; Keykavous Parang; Reza Mehvar
Journal: J Pharm Sci Date: 2008-07 Impact factor: 3.534